These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19730281)

  • 1. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
    Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1α and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Vu D; Tellez-Corrales E; Yang J; Qazi Y; Shah T; Naraghi R; Hutchinson IV; Min DI
    Transpl Immunol; 2013 Dec; 29(1-4):155-61. PubMed ID: 23721685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
    Lloberas N; Torras J; Cruzado JM; Andreu F; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Brunet M; Ekberg H; Grinyó JM;
    Nephrol Dial Transplant; 2011 Nov; 26(11):3784-93. PubMed ID: 21427078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
    Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
    Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
    Fukuda T; Goebel J; Cox S; Maseck D; Zhang K; Sherbotie JR; Ellis EN; James LP; Ward RM; Vinks AA
    Ther Drug Monit; 2012 Dec; 34(6):671-9. PubMed ID: 23131697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Inoue K; Miura M; Satoh S; Kagaya H; Saito M; Habuchi T; Suzuki T
    Ther Drug Monit; 2007 Jun; 29(3):299-304. PubMed ID: 17529886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uridine diphosphate glucuronosyltransferase 2B7 variant p.His268Tyr as a predictor of kidney allograft early acute rejection.
    Pazik J; Ołdak M; Lewandowski Z; Podgórska M; Sitarek E; Płoski R; Gałazka Z; Kwiatkowski A; Malejczyk J; Durlik M
    Transplant Proc; 2013 May; 45(4):1516-9. PubMed ID: 23726609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
    Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
    Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
    Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
    Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications.
    Kleinman L; Faull R; Walker R; Ramesh Prasad GV; Ambuehl P; Bahner U
    Transplant Proc; 2005 Mar; 37(2):846-9. PubMed ID: 15848552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant.
    Ciftci HS; Demir E; Karadeniz MS; Tefik T; Nane I; Oguz FS; Aydin F; Turkmen A
    Ren Fail; 2018 Nov; 40(1):395-402. PubMed ID: 30012031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
    Naesens M; Kuypers DR; Verbeke K; Vanrenterghem Y
    Transplantation; 2006 Oct; 82(8):1074-84. PubMed ID: 17060857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
    Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
    Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients.
    Satoh S; Tada H; Murakami M; Tsuchiya N; Li Z; Numakura K; Saito M; Inoue T; Miura M; Hayase Y; Suzuki T; Habuchi T
    Transplantation; 2006 Aug; 82(4):486-93. PubMed ID: 16926592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
    Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
    Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Kagaya H; Inoue K; Miura M; Satoh S; Saito M; Tada H; Habuchi T; Suzuki T
    Eur J Clin Pharmacol; 2007 Mar; 63(3):279-88. PubMed ID: 17211619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.